Olema Pharmaceuticals, Inc.
OLMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001750284
In the last 90 days, Olema Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 1 sale; 185 institutions reported holding it in 13F filings for Q2 2026, worth $1.28B in total; Duquesne Family Office is the only superinvestor holding it.
Q3 2021 vs. Q2 2021
How the institutions holding Olema Pharmaceuticals, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 69 | 1 | 76 | +8 |
| Shares | 37.4M | 163.1K | 36.7M | −523.8K (−1.4%) |
| Value | $1.05B | $4.57M | $1.01B | −$30.2M (−2.9%) |
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Olema Pharmaceuticals, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Acuta Capital Partners, LLC | 150,500 | $4.15M | 1.48% |
| Pictet Asset Management SA | 150,133 | $4.14M | 0.00% |
| Russell Investments Group, Ltd. | 125,383 | $3.46M | 0.01% |
| Two Sigma Investments, LP | 99,500 | $2.74M | 0.01% |
| Renaissance Technologies LLC | 97,900 | $2.70M | 0.00% |
| Fred Alger Management, LLC | 92,785 | $2.56M | 0.01% |
| Marshall Wace, LLP | 45,578 | $1.26M | 0.01% |
| Mirabella Financial Services LLP | 25,920 | $714.0K | 0.09% |
| Marshall Wace North America L.P. | 25,464 | $701.0K | 0.00% |
| Man Group plc | 14,500 | $400.0K | 0.00% |
| SG Americas Securities, LLC | 14,060 | $387.0K | 0.00% |
| M&T Bank Corp | 10,735 | $296.0K | 0.00% |
| Voya Investment Management LLC | 9,650 | $266.0K | 0.00% |
| Two Sigma Advisers, LP | 9,300 | $256.0K | 0.00% |
| Wells Fargo & Company | 755 | $21.0K | 0.00% |
| Signaturefd, LLC | 104 | $3.00K | 0.00% |
| Captrust Financial Advisors | 6 | $0 | 0.00% |
Sold out (9)
Institutions that held Olema Pharmaceuticals, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Avoro Capital Advisors LLC | 876,986 | $24.5M |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 620,397 | $17.4M |
| Franklin Resources Inc | 412,205 | $11.5M |
| Tybourne Capital Management (HK) Ltd | 239,996 | $6.71M |
| Adage Capital Partners GP, L.L.C. | 225,000 | $6.30M |
| Point72 Asset Management, L.P. | 80,000 | $2.24M |
| Trexquant Investment LP | 12,335 | $345.0K |
| Ensign Peak Advisors, Inc | 9,800 | $275.0K |
| Price T Rowe Associates Inc | 8,623 | $241.0K |
Not filed for Q3 2021 yet (1)
Institutions that held Olema Pharmaceuticals, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Pictet Asset Management Ltd | 163,135 | $4.57M |